Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
805K
-
Number of holders
-
14
-
Total 13F shares, excl. options
-
686K
-
Shares change
-
-21K
-
Total reported value, excl. options
-
$249K
-
Value change
-
-$7.38K
-
Number of buys
-
3
-
Number of sells
-
-1
-
Price
-
$0.36
Significant Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q1 2024
14 filings reported holding INM - InMed Pharmaceuticals Inc. - Common Shares, no par value as of Q1 2024.
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) has 14 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 686K shares
of 805K outstanding shares and own 85.25% of the company stock.
Largest 10 shareholders include SABBY MANAGEMENT, LLC (362K shares), ARMISTICE CAPITAL, LLC (267K shares), RENAISSANCE TECHNOLOGIES LLC (28.3K shares), TWO SIGMA SECURITIES, LLC (15.4K shares), CITADEL ADVISORS LLC (12.7K shares), BFSG, LLC (200 shares), Qube Research & Technologies Ltd (200 shares), BANK OF AMERICA CORP /DE/ (100 shares), AdvisorNet Financial, Inc (80 shares), and UBS Group AG (41 shares).
This table shows the top 14 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.